PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 2, 2026European Heart Journal Acute Cardiovascular Care2 citationsOpen Access

Landiolol for rate control in decompensated heart failure due to atrial fibrillation - the LARISA trial

View Full Paper
MŠMarek ŠramkoABAles BenakJTJakub Toman

Key Result

Landiolol-based intensive rate control in acute heart failure with reduced LVEF achieves faster, safe heart rate reduction and early symptom improvement versus standard therapy.

Key Points

  • To evaluate the efficacy of landiolol for heart rate control in patients with decompensated heart failure and atrial fibrillation.
  • Conducted a trial with intensive rate control using landiolol.
  • Compared outcomes with standard therapy.
  • Focused on patients with acute heart failure and reduced left ventricular ejection fraction (LVEF).
  • Landiolol provided faster heart rate reduction compared to standard therapy.
  • Patients experienced early symptomatic benefits from the intensive treatment.

Structured PICO

Does protocolized landiolol-based intensive rate control improve heart rate reduction and symptoms in patients with acute heart failure and reduced LVEF due to atrial fibrillation?

P
Population
Patients with acute heart failure (AHF) with reduced LVEF due to atrial fibrillation
I
Intervention
Protocolized landiolol-based intensive rate control
C
Comparator
Standard therapy
O
Outcome
Heart rate reduction and early symptomatic benefit

Landiolol-based intensive rate control is effective and safe for rapid heart rate reduction and symptom improvement in acute heart failure with reduced LVEF and atrial fibrillation.

Abstract

In AHF with reduced LVEF, protocolized landiolol-based intensive rate control provides faster and safe HR reduction with early symptomatic benefit compared with standard therapy.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Šramko et al. (2026) studied this question. Landiolol-based intensive rate control in acute heart failure with reduced LVEF achieves faster, safe heart rate reduction and early symptom improvement versus standard therapy.

synapsesocial.com/papers/69a52e56f1e85e5c73bf1e6ahttps://doi.org/10.1093/ehjacc/zuag027
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Urgent Control of Rapid Atrial Fibrillation by Landiolol in Patients With Acute Decompensated Heart Failure With Severely Reduced Ejection Fraction2019 · 22 citations
  2. 2Landiolol for rate control management of atrial fibrillation in patients with cardiac dysfunction2018 · 12 citations
  3. 3Landiolol for managing atrial fibrillation in intensive care2018 · 22 citations
  4. 4A Low-Dose β1-Blocker Effectively and Safely Slows the Heart Rate in Patients with Acute Decompensated Heart Failure and Rapid Atrial Fibrillation2013 · 35 citations
  5. 5Landiolol: pharmacology and its use for rate control in atrial fibrillation in an emergency setting2018 · 29 citations